These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30864146)

  • 1. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
    Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S;
    Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
    J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
    Johnson P; Federico M; Kirkwood A; Fosså A; Berkahn L; Carella A; d'Amore F; Enblad G; Franceschetto A; Fulham M; Luminari S; O'Doherty M; Patrick P; Roberts T; Sidra G; Stevens L; Smith P; Trotman J; Viney Z; Radford J; Barrington S
    N Engl J Med; 2016 Jun; 374(25):2419-29. PubMed ID: 27332902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
    Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
    Stephens DM; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; LaCasce AS; Barr PM; Knopp MV; Hsi ED; Leonard JP; Kahl BS; Smith SM; Friedberg JW
    Blood; 2019 Oct; 134(15):1238-1246. PubMed ID: 31331918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
    André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
    J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
    Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
    Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective.
    Yasenchak C; Liu N; Beeks A; Fanale M; Robert N; He D; Yu KS
    JCO Oncol Pract; 2023 Oct; 19(10):860-870. PubMed ID: 37651672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
    Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Delarue R; Farhat H; Quittet P; Berriolo-Riedinger A; Tempescul A; Edeline V; Maisonneuve H; Fornecker LM; Lamy T; Delmer A; Dartigues P; Martin L; André M; Mounier N; Traverse-Glehen A; Meignan M
    Lancet Oncol; 2019 Feb; 20(2):202-215. PubMed ID: 30658935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Ukrainian multicenter prospective study of the value of PET/ CT prognostic role in primary patients with Hodgkins lymphoma in a real-life cohort.
    Novosad O; Skrypets T; Pastushenko I; Kadnikova T; Gorbach O; Kozlov V; Mykhalska L; Kosinova V; Kostiukova N; Karnabeda O; Stratienko V; Novikov M; Oliinichenko O; Kmetyuk I; Karpova O; Ashykhmin A; Lukjanec O; Kriachok I
    Klin Onkol; 2020; 33(6):450-457. PubMed ID: 33685195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
    Hartridge-Lambert SK; Schöder H; Lim RC; Maragulia JC; Portlock CS
    Cancer; 2013 Mar; 119(6):1203-9. PubMed ID: 23132361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
    Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
    Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
    Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
    J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
    Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
    Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
    Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
    Santoro A; Mazza R; Spina M; Califano C; Specchia G; Carella M; Consoli U; Palombi F; Musso M; Pulsoni A; Kovalchuk S; Bonfichi M; Ricci F; Fabbri A; Liberati AM; Rodari M; Giordano L; Chimienti E; Balzarotti M; Sorasio R; Gallamini A; Ghiggi C; Ciammella P; Ricardi U; Chauvie S; Carlo-Stella C; Merli F
    Ann Hematol; 2021 Oct; 100(10):2547-2556. PubMed ID: 34327561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.